Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai

Canadian Journal of Clinical Pharmacology

Volumn 14, Issue 1, 2007, Pages

  Du, Wenmin ^a   Levine, Mitchell ^b   Wang, Longxing ^c   Zhang, Yaohua ^c   Yi, Chengdong ^c   Wang, Hongmin ^a   Wang, Xiaoyu ^a   Xie, Hongjuan ^a   Xu, Jianglong ^a   Jin, Huilin ^a   Wang, Tongchun ^a   Huang, Gan ^c   Wu, Ye ^c  

^a Adverse Drug Reaction Monitoring Centre of Shanghai   (China)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c Food and Drug Administration of Beijing Xicheng District   (China)

Author keywords

Post marketing; Record linkage; Shanghai

Indexed keywords

CHINA; CONFERENCE PAPER; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG MARKETING; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG UTILIZATION; MEDICAL RECORD; MEDICARE;

EID: 33846694834     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Brian L. Strom. Preface. Pharmacoepidemiology (4th edition, Edited by Brian L. Strom):xv-xvii.
2. Drazen JM. COX-2 inhibitors - a lesson in unexpected problems. N Engl J Med 2005;352:1131-1132.
3. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl JMed 2005;352:1133-1135.
4. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl JMed 2006 Apr 20;354(16):1706-17.
5. th edition, Edited by Brian L. Strom):135-159.
6. Gough S. Post-marketing surveillance: a UK/European perspective. CurrMed Res Opin 2005 Apr;21(4):565-70.
7. Segal ES, Valette C, Oster L, et al. Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf 2005;28(11):971-80.
8. th edition, Edited by Brian L. Strom):219-222.
9. Brian L. Strom. What is pharmacoepidemiology? ibid:3-15.
10. Ralph Edwards, Sten Olsson, Marie Lindquist, Bruce Hugman. Global drug surveillance: the WHO programme for international drug monitoring. ibid:161-183.
11. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999 Mar 3;281(9):824-9.
12. Boyd IW. The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety. Toxicology 2002 Dec 27;181-182:99-102.
13. Crombie I. Inherent limitations of the yellow card system for the detection of unsuspected adverse drug reactions. Hum Toxicol 1984 Aug;3(4):261-9.
14. Liu BA, Knowles SR, Mittmann N, Einarson T, Shear NH. Reporting of fatal adverse drug reactions. Can J Clin Pharmacol 2001 Summer;8(2):84-8.
15. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998 Jul 11;317(7151):119-20.
16. Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. JAMA 2004 Dec 1;292(21):2643-6.
17. th edition, Edited by Brian L. Strom):203-216.
18. Gelfand JM, Margolis DJ, Dattani H. The UK General Practice Research Database. ibid:337-346.
19. Ssunders KW, Davis RL, Stergachis A. Group Health Cooperative. ibid:223-240.
20. Selby JV, Smith DH, Johnson ES, Raebel MA, Friedman GD, McFarland BH. Kaiser Permanente Medical Care Program. ibid:241-260.
21. Chan KA, Davis RL, Gunter MJ, et al. The HMO Research Network. ibid:261-270.
22. Shatin D, Rawson NSB, Stergachis A. United Health Group. ibid:271-280.
23. Hennessy S, Carson JL, Ray WA, Strom BL. Medicaid Databases. ibid:281-294.
24. Downey W, Stang MR, Beck P, Osei W, Nichol JL. Health Services Databases in Saskatchewan. ibid:295-310.
25. Leufkens HG, Urquhart J. Automated Pharmacy Record Linkage in The Netherlands. ibid:311-322.
26. Tang WL, Wang YM, Du WM, Cheng NN, Chen BY. Assessment of quality of life and relevant factors in elderly diabetic patients in the Shanghai community. Pharmacoepidemiol Drug Saf 2006 Feb;15(2):123-30.
27. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy 2006 May;26(5):601-8.